Patient-Reported Outcome Measures in Adult Patients Diagnosed with Epilepsy Being Treated with Perampanel

References

• Kobau R, Price PH, Giles HW, Pennell PB, Hargis E. Centers for disease control and prevention managing epilepsy well network. Epilepsy Behav. 2010;19(3):216–217. doi:10.1016/j.yebeh.2010.08.016
   PubMed Web of Science ®Google Scholar
• Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482. doi:10.1111/epi.12550
   PubMed Web of Science ®Google Scholar
• Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ. 2014;348:g254. doi:10.1136/bmj.g254
   PubMed Web of Science ®Google Scholar
• Perampanel: a new add-on treatment for epilepsy. Drug Ther Bull. 2013;51(2):18–20. doi:10.1136/dtb.2013.1.0159
   PubMedGoogle Scholar
• Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286. doi:10.1001/jamaneurol.2017.3949
   PubMed Web of Science ®Google Scholar
• Tsai JJ, Wu T, Leung H, et al. Perampanel, an AMPA receptor antagonist: from clinical research to practice in clinical settings. Acta Neurol Scand. 2018;137(4):378–391. doi:10.1111/ane.12879
   PubMed Web of Science ®Google Scholar
• Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12(10):757–776. doi:10.1038/nrd4126
   PubMed Web of Science ®Google Scholar
• Wilcox KS, Dixon-Salazar T, Sills GJ, et al. Issues related to development of new antiseizure treatments. Epilepsia. 2013;Suppl 54:24–34. doi:10.1111/epi.12296
   Web of Science ®Google Scholar
• Chong DJ, Lerman AM. Practice update: review of anticonvulsant therapy. Curr Neurol Neurosci Rep. 2016;16(4):39. doi:10.1007/s11910-016-0640-y
   PubMed Web of Science ®Google Scholar
• Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl. 2013;127:3–8. doi:10.1111/ane.12098
   Google Scholar
• Greenwood J, Valdes J. Perampanel (Perampanel): a review of clinical efficacy and safety in epilepsy. P T Drug Forecast. 2016;41(11):683–688.
   Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from Phase III extension study 307. Epilepsia. 2014;55(7):1058–1068. doi:10.1111/epi.12643
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Kwan P, et al. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307. Epilepsia. 2018;59(4):866–876. doi:10.1111/epi.14044
   PubMed Web of Science ®Google Scholar
• Wu T, Nagaya Y, Hanada T. Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model. Seizure. 2014;23(9):732–739. doi:10.1016/j.seizure.2014.06.001
   PubMed Web of Science ®Google Scholar
• Epilepsy Foundation. Perampanel; 2017. Available from: https://www.epilepsy.com/medications/perampanel. Accessed January 19, 2022.
   Google Scholar
• Frampton JE. Perampanel: a review in drug-resistant epilepsy. Drugs. 2015;75(14):1657–1668. doi:10.1007/s40265-015-0465-z
   PubMed Web of Science ®Google Scholar
• Anderson P. FDA okays perampanel monotherapy for partial-onset seizures; 2017. Available from: https://www.medscape.com/viewarticle/883519. Accessed January 19, 2022.
   Google Scholar
• Gil-Nagel A, Burd S, Toledo M, et al. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure. 2018;54:61–66. doi:10.1016/j.seizure.2017.10.015
   PubMed Web of Science ®Google Scholar
• Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7(1):1–10. doi:10.1186/1477-7525-7-36
   PubMed Web of Science ®Google Scholar
• IQVIA.User manual for the treatment satisfaction questionnaire for medication (TSQM): IQVIA; 2018. Available from: https://www.iqvia.com/landing/treatment-satisfaction-questionnaire-for-medication-tsqm. Accessed Febrary 02, 2022.
   Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. doi:10.1097/00005650-198601000-00007
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Thompson TR, Nanry K, Edwards S, Manjunath R. Prospective, open-label trial measuring satisfaction and convenience of two formulations of lamotrigine in subjects with mood disorders. Patient Prefer Adherence. 2013;7:411–417. doi:10.2147/PPA.S40271
   PubMed Web of Science ®Google Scholar
• Sweileh WM, Ihbesheh MS, Jarar IS, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav. 2011;21(3):301–305. doi:10.1016/j.yebeh.2011.04.011
   PubMed Web of Science ®Google Scholar
• Faught E, Laliberté F, Wang Z, et al. Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States. Epilepsia. 2017;58(10):1742–1748. doi:10.1111/epi.13857
   PubMed Web of Science ®Google Scholar
• Li X, Frech F, Plauschinat CA, Gore M. Real-world hospitalization risk in patients with epilepsy treated with perampanel. Epilepsy Behav. 2021;114:107270.
   PubMed Web of Science ®Google Scholar
• Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care. 1975;13(1):10–24. doi:10.1097/00005650-197501000-00002
   PubMed Web of Science ®Google Scholar
• Ferrari CM, de Sousa RM, Castro LH. Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure. 2013;22(5):384–389. doi:10.1016/j.seizure.2013.02.006
   PubMed Web of Science ®Google Scholar
• Jones RM, Butler JA, Thomas VA, Peveler RC, Prevett M. Adherence to treatment in patients with epilepsy: associations with seizure control and illness beliefs. Seizure. 2006;15(7):504–508. doi:10.1016/j.seizure.2006.06.003
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589–596. doi:10.1212/WNL.0b013e3182635735
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117–125. doi:10.1111/j.1528-1167.2012.03638.x
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–1415. doi:10.1212/WNL.0b013e318254473a
   PubMed Web of Science ®Google Scholar
• Glauser T, Laurenza A, Yang H, Williams B, Ma T, Fain R. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: a phase III post-hoc analysis. Epilepsy Res. 2016;119:34–40. doi:10.1016/j.eplepsyres.2015.11.014
   PubMed Web of Science ®Google Scholar
• Trinka E, Lattanzi S, Carpenter K, et al. Exploring the evidence for broad-spectrum effectiveness of perampanel: a systematic review of clinical data in generalised seizures. CNS Drugs. 2021;35(8):821–837. doi:10.1007/s40263-021-00831-y
   PubMed Web of Science ®Google Scholar